Ερευνητικό υλικό ΕΚΠΑ

Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients with Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study

Αγγλικά

Background and Purposes - This study was designed to derive and validate a score to predict early ischemic events and major bleedings after an acute ischemic stroke in patients with atrial fibrillation. Methods - The derivation cohort consisted of 854 patients with acute ischemic stroke and atrial fibrillation included in prospective series between January 2012 and March 2014. Older age (hazard ratio 1.06 for each additional year; 95% confidence interval, 1.00-1.11) and severe atrial enlargement (hazard ratio, 2.05; 95% confidence interval, 1.08-2.87) were predictors for ischemic outcome events (stroke, transient ischemic attack, and systemic embolism) at 90 days from acute stroke. Small lesions (≤1.5 cm) were inversely correlated with both major bleeding (hazard ratio, 0.39; P=0.03) and ischemic outcome events (hazard ratio, 0.55; 95% confidence interval, 0.30-1.00). We assigned to age ≥80 years 2 points and between 70 and 79 years 1 point; ischemic index lesion >1.5 cm, 1 point; severe atrial enlargement, 1 point (ALESSA score). A logistic regression with the receiver-operating characteristic graph procedure (C statistic) showed an area under the curve of 0.697 (0.632-0.763; P=0.0001) for ischemic outcome events and 0.585 (0.493-0.678; P=0.10) for major bleedings. Results - The validation cohort consisted of 994 patients included in prospective series between April 2014 and June 2016. Logistic regression with the receiver-operating characteristic graph procedure showed an area under the curve of 0.646 (0.529-0.763; P=0.009) for ischemic outcome events and 0.407 (0.275-0.540; P=0.14) for hemorrhagic outcome events. Conclusions - In acute stroke patients with atrial fibrillation, high ALESSA scores were associated with a high risk of ischemic events but not of major bleedings. © 2017 American Heart Association, Inc.

2017

Paciaroni, M.
Agnelli, G.
Caso, V.
Tsivgoulis, G.
Furie, K.L.
Tadi, P.
Becattini, C.
Falocci, N.
Zedde, M.
Abdul-Rahim, A.H.
Lees, K.R.
Alberti, A.
Venti, M.
Acciarresi, M.
D'Amore, C.
Mosconi, M.G.
Cimini, L.A.
Procopio, A.
Bovi, P.
Carletti, M.
Rigatelli, A.
Cappellari, M.
Putaala, J.
Tomppo, L.
Tatlisumak, T.
Bandini, F.
Marcheselli, S.
Pezzini, A.
Poli, L.
Padovani, A.
Masotti, L.
Vannucchi, V.
Sohn, S.-I.
Lorenzini, G.
Tassi, R.
Guideri, F.
Acampa, M.
Martini, G.
Ntaios, G.
Karagkiozi, E.
Athanasakis, G.
Makaritsis, K.
Vadikolias, K.
Liantinioti, C.
Chondrogianni, M.
Mumoli, N.
Consoli, D.
Galati, F.
Sacco, S.
Carolei, A.
Tiseo, C.
Corea, F.
Ageno, W.
Bellesini, M.
Colombo, G.
Silvestrelli, G.
Ciccone, A.
Scoditti, U.
Denti, L.
Mancuso, M.
Maccarrone, M.
Orlandi, G.
Giannini, N.
Gialdini, G.
Tassinari, T.
De Lodovici, M.L.
Bono, G.
Rueckert, C.
Baldi, A.
D'Anna, S.
Toni, D.
Letteri, F.
Giuntini, M.
Lotti, E.M.
Flomin, Y.
Pieroni, A.
Kargiotis, O.
Karapanayiotides, T.
Monaco, S.
Baronello, M.M.
Csiba, L.
Szabó, L.
Chiti, A.
Giorli, E.
Del Sette, M.
Imberti, D.
Zabzuni, D.
Doronin, B.
Volodina, V.
Michel, P.
Vanacker, P.
Barlinn, K.
Pallesen, L.-P.
Kepplinger, J.
Bodechtel, U.
Gerber, J.
Deleu, D.
Melikyan, G.
Ibrahim, F.
Akhtar, N.
Gourbali, V.
Yaghi, S.

ISRN Stroke

Lippincott Williams and Wilkins

48

3

726-732

anticoagulant agent; anticoagulant agent; warfarin, aged; anticoagulant therapy; Article; atrial fibrillation; cardiovascular risk; cerebrovascular accident; computer assisted tomography; early diagnosis; early intervention; female; heart atrium enlargement; human; major clinical study; male; nuclear magnetic resonance; observational study; outcome assessment; priority journal; prospective study; recurrence risk; risk assessment; thromboembolism; transient ischemic attack; transthoracic echocardiography; atrial fibrillation; bleeding; chemically induced; complication; Ischemic Attack, Transient; procedures; recurrent disease; Stroke; thromboembolism; very elderly, Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Prospective Studies; Recurrence; Risk Assessment; Stroke; Thromboembolism; Warfarin

https://doi.org/10.1161/STROKEAHA.116.015770

10.1161/STROKEAHA.116.015770

https://pergamos.lib.uoa.gr/uoa/dl/object/2988040